Eli Lilly and Company Pumps $700 Million To Boost Insulin Making Capacity
Eli Lilly and Co said it will invest more than $700 million to boost its insulin manufacturing capacity in Puerto Rico, France, China and the United States.
The company's traditional stronghold has been its diabetes treatments, but the sales of its drugs have been suffering due to increasing competition from companies including Denmark's Novo Nordisk.
Help employers find you! Check out all the jobs and post your resume.